BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11156225)

  • 1. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.
    Smith AM; Justin T; Michaeli D; Watson SA
    Clin Cancer Res; 2000 Dec; 6(12):4719-24. PubMed ID: 11156225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer.
    Watson SA; Michaeli D; Grimes S; Morris TM; Robinson G; Varro A; Justin TA; Hardcastle JD
    Cancer Res; 1996 Feb; 56(4):880-5. PubMed ID: 8631028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5.
    Watson SA; Michaeli D; Grimes S; Morris TM; Crosbee D; Wilkinson M; Robinson G; Robertson JF; Steele RJ; Hardcastle JD
    Int J Cancer; 1995 Apr; 61(2):233-40. PubMed ID: 7705954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of G17DT in gastric carcinoma.
    Gilliam AD; Watson SA; Henwood M; McKenzie AJ; Humphreys JE; Elder J; Iftikhar SY; Welch N; Fielding J; Broome P; Michaeli D
    Eur J Surg Oncol; 2004 Jun; 30(5):536-43. PubMed ID: 15135483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy.
    Watson SA; Gilliam AD
    Expert Opin Biol Ther; 2001 Mar; 1(2):309-17. PubMed ID: 11727538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
    Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
    Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
    Rocha-Lima CM; de Queiroz Marques Junior E; Bayraktar S; Broome P; Weissman C; Nowacki M; Leslie M; Susnerwala S
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):479-86. PubMed ID: 25030089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV.
    Watson SA; Michaeli D; Morris TM; Clarke P; Varro A; Griffin N; Smith A; Justin T; Hardcastle JD
    Eur J Cancer; 1999 Aug; 35(8):1286-91. PubMed ID: 10615243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gastrin-17 and G17-gly induce proliferation of LoVo cells through the CCK B/gastrin receptor].
    Artru P; Attoub S; Levasseur S; Lewin MJ; Bado A
    Gastroenterol Clin Biol; 1998; 22(6-7):607-12. PubMed ID: 9762332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.
    Brett BT; Smith SC; Bouvier CV; Michaeli D; Hochhauser D; Davidson BR; Kurzawinski TR; Watkinson AF; Van Someren N; Pounder RE; Caplin ME
    J Clin Oncol; 2002 Oct; 20(20):4225-31. PubMed ID: 12377966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition.
    Sebens Müerköster S; Rausch AV; Isberner A; Minkenberg J; Blaszczuk E; Witt M; Fölsch UR; Schmitz F; Schäfer H; Arlt A
    Oncogene; 2008 Feb; 27(8):1122-34. PubMed ID: 17704804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
    Hartwich J; Konturek SJ; Pierzchalski P; Zuchowicz M; Konturek PC; Bielański W; Marlicz K; Starzyńska T; Ławniczak M
    Med Sci Monit; 2001; 7(6):1171-81. PubMed ID: 11687726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT.
    BioDrugs; 2003; 17(3):223-5. PubMed ID: 12749761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
    Watson SA; Smith AM
    Cancer Res; 2001 Jan; 61(2):625-31. PubMed ID: 11212260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
    Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
    J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.
    Haigh CR; Attwood SE; Thompson DG; Jankowski JA; Kirton CM; Pritchard DM; Varro A; Dimaline R
    Gastroenterology; 2003 Mar; 124(3):615-25. PubMed ID: 12612900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
    Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
    Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
    Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.